Shares of Palatin Technologies Inc. PTN, +4.69% rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on
, +4.06% treatment for hypoactive sexual desire disorder triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for 's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with
BringeReprobate
Australia Australia Latest News, Australia Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Believing all this talk about a stock market bubble can land you in real troubleS&P 500 gains aren’t large enough to prove the market is overheated, writes Mark Hulbert.
Read more »